Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Public ClinicalTrials.gov record NCT02987543. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.
Study identification
- NCT ID
- NCT02987543
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 387 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 6, 2017 (Actual)
- Primary completion
- Jun 4, 2019 (Actual)
- Completion
- Feb 15, 2023 (Actual)
- Last update posted
- Oct 6, 2023
2017 – 2023
United States locations
- U.S. sites
- 35
- U.S. states
- 23
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anchorage | Alaska | 99503 | — |
| Research Site | Tucson | Arizona | 85704 | — |
| Research Site | Tucson | Arizona | 85741 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | San Diego | California | 92161 | — |
| Research Site | Santa Barbara | California | 93105 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Atlanta | Georgia | 30318 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Jeffersonville | Indiana | 47130 | — |
| Research Site | New Orleans | Louisiana | 70112 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Omaha | Nebraska | 68130 | — |
| Research Site | Las Vegas | Nevada | 89135 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | Brooklyn | New York | 11201 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | The Bronx | New York | 10468 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Salisbury | North Carolina | 28144 | — |
| Research Site | Columbus | Ohio | 43230 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Springfield | Oregon | 97477 | — |
| Research Site | Tualatin | Oregon | 97062 | — |
| Research Site | Charleston | South Carolina | 29401 | — |
| Research Site | Myrtle Beach | South Carolina | 29572 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
| Research Site | Salt Lake City | Utah | 84148 | — |
| Research Site | Spokane | Washington | 99202 | — |
| Research Site | Wheeling | West Virginia | 26003 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02987543, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02987543 live on ClinicalTrials.gov.